BTIG analyst Mark Massaro has reiterated their neutral stance on CERS stock, giving a Hold rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mark Massaro has given his Hold rating due to a combination of factors related to Cerus’s leadership transition and valuation. The move to elevate current COO Vivek Jayaraman to CEO, with long‑time CEO Obi Greenman becoming Executive Chairman, is viewed as orderly and low risk, and Massaro does not expect meaningful changes to the company’s strategic direction or to his financial forecasts.
At the same time, the stock already trades around 1.6x his 2026 revenue estimate, which he judges to be broadly in line with comparable small‑cap peers. While he acknowledges solid progress in product approvals, commercial execution, and a path toward positive adjusted EBITDA in 2026, he does not see a sufficiently compelling discount or upside catalyst at current levels to justify a more positive stance, leading him to maintain a Neutral/Hold view on CERS.
According to TipRanks, Massaro is an analyst with an average return of -4.8% and a 31.90% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Personalis, GeneDx Holdings, and Cerus.
In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $1.50 price target.